BeOne Medicines AG (ONC) on Decifer

Decifer ranks ONC number 251 of 277 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 5% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 40% a year and profits grew 652% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Revenue growing about 40% with profits up 652% is striking, but returns near 5%, no clean read on management, and no worldview role keep it speculative.

The current read

The evidence on ONC lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: BeOne Medicines AG operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full ONC research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.